List of Tables

Table 2.1	Drug Profile
Table 2.2	Inherent viscosity and molecular weight for PLGA 50:50 (Purac Biomaterials)
Table 2.3	Human mAbs approved or under FDA review
Table 3.1	Absorbance of Docetaxel in Acetonitrile
Table 4.1	Variables in Box–Behnken design
Table 4.2	Formulation of Docetaxel loaded nanoparticles with coded values
Table 4.3	Composition and observed responses in Box–Behnken design
Table 4.4	Summary of ANOVA results for Different Models
Table 4.5	ANOVA Table for Response Surface linear Model
Table 4.6	Summary of ANOVA results for Quadratic Model
Table 4.7	Summary of ANOVA results for Different Models
Table 4.8	ANOVA Table for Response Surface linear Model
Table 4.9	Summary of ANOVA results for Quadratic Model
Table 4.10	Summary of ANOVA results for Different Models
Table 4.11	ANOVA Table for Response Surface linear Model
Table 4.12	Summary of ANOVA results for Quadratic Model
Table 4.13	Constraints Applied for Selection of Optimized Batch
Table 4.14	Experimental Confirmation of the Predicted Responses
Table 4.15	Effect of different cryoprotectants on the particle size and redispersion of NG nanoparticles
Table 4.16	Optimization of antibody-conjugation activation pH

Table 4.17	Optimization of antibody conjugation reaction temperature
Table 4.18	Optimization of amount of activating agent
Table 4.19	Optimization of antibody conjugation reaction time
Table 4.20	Optimization of amount of antibody
Table 5.1	Percent viability of A549 cells treated with various concentrations of Docetaxel at different incubation time period
Table 5.2	Percent viability of A549 cells treated with various concentrations of Docetaxel Nanoparticles at different incubation time period
Table 5.3	Percent viability of A549 cells treated with various concentrations of Cetuximab conjugated Docetaxel Nanoparticles at different incubation time period
Table 7.1	Stability Testing Data of Docetaxel Nanoparticles